Years into the pandemic, only a handful of clinical trials are targeting long COVID — here’s one of them

Scientists at Stanford are testing Pfizer’s Paxlovid on long COVID symptoms and their efforts could provide clues for other conditions.  

By Kelly Bilodeau • May 15, 2023

How pharma’s rocky real estate market has changed — for better and worse

Whether you’re looking to build a new site or expand lab space, here are the biggest trends impacting life sciences real estate.

By Karissa Waddick • May 11, 2023

Explore the Trendline➔

Oncology

As investments in cancer R&D stay high, waves of innovative new treatments are on the horizon.

By PharmaVoice staff

AbbVie’s Christopher Boone on RWE’s potential — and its ‘profound ethical dilemmas’

With decades of experience in public health, Boone is leveraging RWE to move the needle within clinical development.

By Taren Grom • May 10, 2023

Woman of the Week: Reneo Pharmaceuticals’ Ashley Hall

After ushering a blockbuster to market, the chief development officer is channeling her experience into the rare disease space.

By Taren Grom • May 10, 2023

This ‘hot-blooded’ CEO is aiming to transform the way burn victims heal

Cutiss CEO Daniela Marino is funneling her bold personality and expertise in regenerative medicine into a startup developing bioengineered skin grafts.

By Alexandra Pecci • May 9, 2023

How Immunocore’s Bahija Jallal embraced the ‘a-ha’ moment of promising science

The biotech CEO is bullish on the company’s pioneering T cell receptor platform and innovating new immunology-based treatments.

By Taren Grom • May 5, 2023

Woman of the Week: Jazz Pharmaceuticals’ Neena Patil

Patil’s dual interests in healthcare and law are at the intersection of her C-suite role.

By Taren Grom • May 3, 2023

A CEO’s quest to solve a 400-year-old medical mystery — and he’s also a patient

The CEO of Ventoux Biosciences has the disease that his company is aiming to treat, and it's driving him to find better medications.

By Taren Grom • May 1, 2023

Emalex aims at a first-in-class breakthrough for Tourette syndrome

With its phase 3 candidate, the biotech believes it can move the field beyond antipsychotics to a more effective approach.

By Kelly Bilodeau • May 1, 2023

5 minutes with — DTRA’s Dr. Amir Kalali

An industry veteran, innovator and curator, Dr. Amir Kalali discusses the high points of his career and his go-to productivity hack.

By Taren Grom • April 28, 2023

Scientists could finally be closing in on a ‘pill’ for men

Drug developers have tried — and failed — to create a male contraceptive for decades. Now, one group of scientists might be on the verge of success.

By Kelly Bilodeau • April 26, 2023

20 years on, the next stage of the human genome revolution is brewing

Two decades after the Human Genome Project, scientists are on the brink of uncovering its full potential for drug development.

By Karissa Waddick • April 24, 2023

Tuberculosis is the world’s deadliest infectious disease — and treatments remain underfunded

Tuberculosis control and funding lost 20 years of progress during the COVID-19 pandemic, but scientists and world health groups are still plugging away.

By Alexandra Pecci • April 24, 2023

Depression has long been treated chronically — Sage wants to change that

Sage Therapeutics is planning a launch of its newest med, and its chief business officer explains how it could upend the way depression has long been treated.

By Michael Gibney • April 18, 2023

A CMO’s quest to tackle infectious diseases leads him to an eye condition that’s often overlooked

How an “international” childhood sent Dr. José Trevejo, Tarsus’s chief medical officer, on a mission to fight infectious diseases.

By Alexandra Pecci • April 18, 2023

5 minutes with — Genlantis Diagnostics’ Ahsan Awan

A serial entrepreneur, futurist and industry disrupter, the VP of clinical development and digital health is always on the quest to build a “better mousetrap.”

By Taren Grom • April 14, 2023

What’s pharma doing wrong to improve trial diversity? ‘Everything’

Pharma’s missing the mark when it comes to recruiting Black patients, and Ricki Fairley, CEO of The Black Breast Cancer Alliance, reveals what’s needed.

By Karissa Waddick • April 12, 2023

Woman of the Week: uMotif’s Julia Lakeland

The chief product officer’s work in transforming clinical trial technology is driven by people.

By Taren Grom • April 12, 2023

Where one unicorn struggled, another biotech is aiming for a diabetes win

Intarcia looked poised to break into a lucrative diabetes implant market but has been dogged by safety issues — now Vivani thinks it’s found a way to succeed.

By Kelly Bilodeau • April 10, 2023

Despite J&J’s exit, Big Pharma is closing in on a launch of the first RSV vax this year

Although Janssen bowed out of the RSV vaccine race, several pharmas are quickly closing in on the finish line in a disease with decades of unmet need.

By Michael Gibney • April 6, 2023

Woman of the Week: Intergalactic Therapeutics’ Dr. Theresa Heah

Welcome to the Woman of the Week podcast, a weekly discussion that illuminates the unique stories of women leaders who are catalyzing change throughout the life sciences industry. You can check out all our podcast episodes here. Dr. Theresa Heah has spent her entire career moving ophthalm...

By Taren Grom • April 5, 2023

Amgen’s aim for a ‘moonshot’ in cardiovascular disease

A VP of global development at Amgen explains how treating general medicine diseases could one day resemble approaches in oncology.  

By Taren Grom • April 5, 2023

Moderna exec: ‘There is nothing but global health’

How Chantal Friebertshäuser is helping lead Moderna’s plan to expand its global reach.  

By Alexandra Pecci • April 4, 2023

All eyes turn to Karuna as it aims for an approval of a would-be blockbuster

In the red-hot race for new schizophrenia treatments, Karuna Therapeutics is close to an FDA submission.

By Kelly Bilodeau • April 3, 2023

Digital biomarkers lay the groundwork for precision medicine beyond the bloodwork

Biomarkers are the hidden talent behind precision medicine, and finding them doesn't have to always come from a blood test — digital pioneers are finding another way.

By Michael Gibney • March 30, 2023